ClinicalTrials.gg
CompletedNCT03083821Updated Nov 18, 2023Results posted

A Study to Provide a Better Understanding of Baraclude's Pharmacokinetic Properties in a Real World Clinical Setting

A Phase 1 interventional study of Baraclude in Hepatitis B Virus, sponsored by Bristol-Myers Squibb. Completed at 1 site in Japan. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
20 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies testing entecavir in Hepatitis B — 6 open to participants now, 9 under way, none of them phase 3. entecavir · Hepatitis B.

Enrollment
36th of 36
6 · median 106
Started
2017
with 2 others
Phase 1
2 of 37
none open now
Registered
26th of 37
by date
Lead sponsor
6 of 37
Bristol-Myers Squibb

Among the 37 studies testing entecavir in Hepatitis B, this one is the 36th largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2017, is one of 2 in phase 1, and was the 26th registered.

Hepatitis B

1,046 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.

Browse Hepatitis B studies →

Open to participants now

6 of the 37 studies testing entecavir in Hepatitis B are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About entecavir

entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 20 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies testing entecavir in Hepatitis B, or all of them as a file.
02

Study summary

A Pharmacokinetics study of Baraclude in a real world clinical setting in Japan.

03

Conditions studied

  • Hepatitis B Virus

Browse trials for

04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com.

  • Participants with chronic (CHB) (excluding participants with a superinfection) who have been confirmed to have CHB.
  • Participants who are being treated with 0.5 mg daily Baraclude for a minimum of 10 consecutive days prior to the study enrollment.
  • (BMI) of 18.5 to 30 kg/m2 (BMI = body weight [kg]/height [m]2)

Exclusion criteria

Exclusion Criteria:

  • Current or recent (within 3 months of Baraclude administration) gastrointestinal disease that could impact upon the absorption of study drug.
  • Any gastrointestinal surgery that could impact upon the absorption of study drug.
  • Donation of blood to a blood bank or in a clinical study (except a screening visit) within 4 weeks of study drug administration (within 2 weeks for plasma only).

Other protocol defined inclusion/exclusion criteria could apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Arm A

    Drug: Baraclude

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Cmax is defined as the peak plasma concentration

    Time frame: Up to 24 hours

  2. Time of Maximum Observed Plasma Concentration (Tmax)

    Tmax is defined as the time of maximum observed plasma concentration, measured in hours

    Time frame: Up to 24 hours

  3. Trough Observed Plasma (Predose) Concentration (Ctrough)

    Ctrough is defined as the trough in observed plasma (predose) concentrations

    Time frame: prior to administration of drug (predose)

  4. Observed Plasma Concentration at 24 Hours Postdose (C24)

    C24 is defined as the observed plasma concentration at 24 hours post-dose

    Time frame: 24 hours post-dose

  5. Area Under the Concentration-time Curve in One Dosing Interval [AUC(TAU)]

    AUC(TAU) is defined as the area under the concentration-time curve in one dosing interval

    Time frame: Up to 24 hours

  6. Apparent Total Body Clearance (CLT/F)

    CLT/F is defined as the apparent total body clearance

    Time frame: Up to 24 hours

07

Results

Posted Nov 18, 2023

Participant flow

Participant flow — Overall Study
MilestoneBaraclude
Started6
Completed6
Not completed0

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax)

Cmax is defined as the peak plasma concentration

Time frame:
Up to 24 hours
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax)
ng/mLBaraclude
Maximum Observed Plasma Concentration (Cmax)8.17 ± 2.517
PrimaryTime of Maximum Observed Plasma Concentration (Tmax)

Tmax is defined as the time of maximum observed plasma concentration, measured in hours

Time frame:
Up to 24 hours
Reported as:
Mean · Hours
Time of Maximum Observed Plasma Concentration (Tmax)
HoursBaraclude
Time of Maximum Observed Plasma Concentration (Tmax)0.667 ± 0.2582
PrimaryTrough Observed Plasma (Predose) Concentration (Ctrough)

Ctrough is defined as the trough in observed plasma (predose) concentrations

Time frame:
prior to administration of drug (predose)
Reported as:
Mean · ng/mL
Trough Observed Plasma (Predose) Concentration (Ctrough)
ng/mLBaraclude
Trough Observed Plasma (Predose) Concentration (Ctrough)0 ± 0
PrimaryObserved Plasma Concentration at 24 Hours Postdose (C24)

C24 is defined as the observed plasma concentration at 24 hours post-dose

Time frame:
24 hours post-dose
Reported as:
Mean · ng/mL
Observed Plasma Concentration at 24 Hours Postdose (C24)
ng/mLBaraclude
Observed Plasma Concentration at 24 Hours Postdose (C24)0.435 ± 0.0678
PrimaryArea Under the Concentration-time Curve in One Dosing Interval [AUC(TAU)]

AUC(TAU) is defined as the area under the concentration-time curve in one dosing interval

Time frame:
Up to 24 hours
Reported as:
Mean · h*ng/mL
Area Under the Concentration-time Curve in One Dosing Interval [AUC(TAU)]
h*ng/mLBaraclude
Area Under the Concentration-time Curve in One Dosing Interval [AUC(TAU)]21.8 ± 4.53
PrimaryApparent Total Body Clearance (CLT/F)

CLT/F is defined as the apparent total body clearance

Time frame:
Up to 24 hours
Reported as:
Mean · mL/min
Apparent Total Body Clearance (CLT/F)
mL/minBaraclude
Apparent Total Body Clearance (CLT/F)397 ± 81.7

Adverse events

Collected over AE information should begin at initiation of study treatment until 100 days after discontinuation. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Baraclude0/6 (0%)0/6 (0%)0/6 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Baraclude
Mean55.0 ± 9.96
Sex: Female, Male
Sex: Female, Male(Participants)Baraclude
Female1
Male5
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Baraclude
Number6
08

Study locations

1 site
  • Local Institution
    Hachioji-shi, Tokyo 1920071, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Dec 2017, 7 months.

Results were first posted in Nov 2023, 5 years 10 months after primary completion.

Of 49 industry-sponsored phase 1 interventional studies under Hepatitis B, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 24. This study's 7 months is below that.

Counting every sponsor, half of 58 studies reached it within 14 months; a quarter within 7 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2017
First posted
Mar 20, 2017
StartActual
May 16, 2017
Primary completionActual
Dec 19, 2017
CompletionActual
Dec 19, 2017
Results first posted
Nov 18, 2023
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03083821
Responsible party
Sponsor
First posted
Mar 20, 2017
Start date
May 16, 2017
Primary completion
Dec 19, 2017
Completion
Dec 19, 2017
Results posted
Nov 18, 2023
Last update
Nov 18, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Entecavir

Start the discussion